WO2006025583A1 - S/o型外用剤 - Google Patents
S/o型外用剤 Download PDFInfo
- Publication number
- WO2006025583A1 WO2006025583A1 PCT/JP2005/016355 JP2005016355W WO2006025583A1 WO 2006025583 A1 WO2006025583 A1 WO 2006025583A1 JP 2005016355 W JP2005016355 W JP 2005016355W WO 2006025583 A1 WO2006025583 A1 WO 2006025583A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oil
- fatty acid
- acid ester
- external preparation
- surfactant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention relates to an SZO (Solid-in-Oi1) type external preparation excellent in transdermal absorbability.
- Non-sterolide anti-inflammatory analgesics (hereinafter referred to as “NSA ID”) are widely used for their excellent anti-inflammatory analgesic properties.
- NSA ID Non-sterolide anti-inflammatory analgesics
- the drug is well known to cause gastrointestinal disorders, especially gastric mucosal disorders such as gastric ulcers and gastric perforation.
- a typical NS AID, aspirin has been used for more than 100 years since its discovery, but in the United States, gastrointestinal disorders cause hospitalization of 5-10 million people a year and more than 2000 people die. It is said. When combined with the side effects of NS A ID other than aspirin, it is estimated that nearly 20,000 people die each year.
- NS AID's external preparation has the advantage that it can be directly applied to the affected area and gastrointestinal disorders are unlikely to occur.
- NS AID has extremely low skin permeability. This is presumably because NS AID has a carboxyl group as a substituent and has a high hydrophilicity, and therefore cannot penetrate the epidermis composed of the stratum corneum. As a result, NS AID could not be delivered to the affected area even as an external preparation, and there was a problem that sufficient effects could not be obtained.
- Other drugs are difficult to use as external preparations due to their high hydrophilicity, and some are developed mainly as oral preparations. As described above, if such a hydrophilic drug can be used as an external preparation, not only side effects can be suppressed, but also the sustainability of medicinal effects can be improved.
- the present inventors dispersed an lyophilized mixture of an aqueous solution of an enzyme, a physiologically active peptide or a drug and an organic solvent solution of a surfactant (S / O type preparation, Solid in Oil) in an oil phase.
- S / O type preparation Solid in Oil
- an SZOZW type formulation in which this is dispersed in an aqueous phase has been developed (JP 2004-43355 A; S. Okazaki, N. Kamiya, K. Abe, M. Goto, F. Nakashio, Biotechnol. Bioeng , 55 (2), 455-460 (1997); N. Kamiya, S. Okazaki, M. Goto, Biotechnol.
- JP-A-6-303973 discloses a surfactant-coated enzyme composition
- a surfactant-coated enzyme composition comprising a surfactant, an enzyme, water and a salt and having high activity even in a water-insoluble organic solvent.
- Japanese translation of PCT publication No. 2003-501404 there is described a preparation in which solid particles composed of a dehydrated product of a drug, a surfactant and a membrane permeation accelerator are suspended in a delivery medium. The preparation can absorb a therapeutic protein or peptide from the mucous membrane in the mouth or nose such as the tongue.
- Japanese National Publication No. 10-510256 discloses a method for preparing a hydrophobic preparation in which a hydrophobic solvent is supplied around a hydrophilic substance coated with an amphiphilic substance. Disclosure of the invention
- hydrophilic drugs have extremely low skin permeability, their effects cannot be fully demonstrated when used as external preparations. Nevertheless, there is an example in which a hydrophilic drug is blended with an external preparation. However, this drug increases the skin permeability of hydrophilic drugs by adding an organic solvent such as isopropanol to the formulation. Therefore, a rash caused by the organic solvent may occur.
- the present inventors made extensive studies on the constituents of external preparations. As a result, the present inventors completed the present invention by discovering the surprising finding that the S / O type formulation that the inventors have already developed increases the skin permeability of hydrophilic drugs.
- the s zo type external preparation of the present invention is such that a drug-containing complex excellent in transdermal absorbability is dissolved or dispersed in an oil phase, and the complex has a hydrophilic drug by a surfactant. It is characterized by being in a solid state being coated.
- the method for improving the transdermal absorbability of the hydrophilic drug according to the present invention includes:
- FIG. 3 is a photograph of a rabbit ear with a diclofenac sodium-S ZO suspension applied to the present invention (A) and a photograph of a rabbit ear with a conventional diclofenac sodium topical preparation applied (B).
- A a photograph of a rabbit ear with a diclofenac sodium-S ZO suspension applied to the present invention
- B a photograph of a rabbit ear with a conventional diclofenac sodium topical preparation applied
- the s / o type external preparation of the present invention is such that a drug-containing complex having excellent transdermal absorbability is dissolved or dispersed in an oil phase, and the complex has a hydrophilic drug as a surfactant. It is characterized in that it is in a solid state coated with.
- the drug-containing complex constituting the SZO type external preparation of the present invention
- the drug-containing complex includes a hydrophilic drug and a surfactant as main components. Then, the hydrophilic part of the surfactant is associated with the drug and the surroundings are covered.
- the complex may be composed of only a hydrophilic drug and a surfactant, or may contain a formulation component that is acceptable in a pharmaceutical formulation. Good.
- hydrophilic drug is used is that the purpose of the present invention is to improve the transdermal absorbability of a hydrophilic drug that has a very low transdermal absorbability compared to a hydrophobic drug.
- hydrophilic drugs are not particularly limited, for example, NSAIDs such as diclofenac natrium indomethacin; angiotensin converting enzyme inhibitors,] 3 blockers, calcium antagonists, angiotensin II receptor antagonists, etc.
- anti-anxiety drugs such as 5- HT 3 antagonists; antihypertensives anti-epileptic agents, stimulants, anti-Parkinson's agents, psychotropic agents, local anesthetics, skeletal muscle relaxants; autonomic nervous agent; Town ⁇ Agent; cardiotonic agent; arrhythmia agent; diuretic agent; antihypertensive agent; vasodilator; hyperlipidemia agent; antitussive agent; expectorant; bronchodilator; antidiarrheal agent; peptic ulcer agent; Hormonal agents such as adrenal hormone agents, male hormone agents, follicular hormones, luteinizing hormone agents; urinary organ agents; uterine contractors; liver disease agents; antidote agents; gout treatment agents; enzyme preparations; An antimetabolite; an antihistamine; an anti-leprosy agent; a synthetic antibacterial agent; an antiviral agent; an antiprotozoal agent; a sulfa agent; a
- the molecular weight of the hydrophilic drug in is preferably 10 or less, more preferably 5, 00 or less, and still more preferably 1, 00 or less.
- diclonanacunatrium As a hydrophilic drug, diclonanacunatrium can be mentioned in particular. Although diclofenac sodium is commercialized as an external preparation, its skin permeability is not yet sufficient, and it causes rashes caused by organic solvents such as isopropanol. However, it is demonstrated in the examples described later that the skin permeability can be improved by the present invention.
- the surfactant can be used without particular limitation as long as it is acceptable in pharmaceutical preparations.
- examples include nonionic surfactants, anionic surfactants, cationic surfactants, amphoteric surfactants, and bile salts.
- Nonionic surfactants include polyglycerin condensed ricinoleic acid ester, decaglycerin ester, glycerin fatty acid ester, polyglycerin fatty acid ester, polyoxyethylene glycerin fatty acid ester, sorbitan fatty acid ester, polyoxyethylene sorbite fatty acid ester, Polyoxyethylene castor oil 'hardened castor oil, sucrose fatty acid ester (sucrose stearate ester, sucrose palmitate ester, sucrose myristate ester, sucrose oleate ester, sucrose laurate ester, sucrose Sugar succinate, sucrose mixed fatty acid ester) and the like. One of these may be used, or a mixture of two or more may be used.
- ester compounds derived from unsaturated fatty acids such as gallic acid oleic acid are preferred, and sucrose erucic acid esters, sucrose oleic acid esters, Examples thereof include sugar mixed fatty acid esters. Or selected from the group consisting of glycerin fatty acid ester, polyglycerin fatty acid ester, polyoxyethylene glycerin fatty acid ester, sorbitan fatty acid ester, sucrose fatty acid ester, polyoxyethylene sorbite fatty acid ester, polyoxyethylene castor oil and hydrogenated castor oil 1 or 2 or more can be used.
- the surfactant it is preferable to use a highly hydrophobic one having an HLB value of 10 or less. This is because the drug-containing complex can be easily dissolved or dispersed in the oil phase.
- a stabilizer may be added to the drug-containing complex of the present invention.
- the stabilizing agent used in the present invention a hydrophilic protein or polysaccharide having a molecular weight of 10 or more is preferably used. The stabilizer can improve the stability of the complex by being covered with the surfactant together with the drug, and can prevent the drug from leaking out of the complex in the external preparation.
- proteins that are stabilizers include serum albumin (molecular weight: about 67,00), ovalbumin (molecular weight: about 45,00), casein (molecular weight: about 19,00,00) Lysozyme (molecular weight: about 14,00 or more), lipase (molecular weight: about 45,00, 0), etc. Select one of these, or 2 or more Can be mixed and used after selection. Preferably, one or more selected from the group consisting of serum albumin, ovalbumin, and casein can be used.
- polysaccharides that are stabilizers include LM pectin, HM pectin, hydroxypropylmethylcellulose phthalate, heparin, alginic acid, and carboxymethylcellulose, and one of these is selected. Or two or more can be selected and mixed for use. Preferably, one or more selected from the group consisting of LM pectin, HM pectin and hydroxypropylmethylcellulose phthalate can be used.
- the molecular weight of the above proteins and polysaccharides varies depending on their origin.
- the general molecular weight of pectin is 50, 0 0 0 to 1 5 0, 0 0 0, but the molecular weight of pectin used in the examples described later is 2 0, 0 0 0 to 4 0, 0 0 0.
- the molecular weights of those exemplified above can generally be 10 0, 0 0 0 or more.
- the molecular weight here may be referred to the power tag value of the protein and polysaccharide used, but if it is unknown, it may be measured as the number average molecular weight.
- the mass ratio of the stabilizer to the hydrophilic drug is from 0.01 to
- a range of 100 is preferred. If it is less than 0.1, the effect may not be sufficiently exhibited. If it exceeds 100, the amount of the drug in the complex decreases, and the original effect of the drug may not be exhibited. . More preferably, it is in the range of 0.1 to 10, more preferably in the range of 0.5 to 5.
- the surface activity relative to the total of the hydrophilic drug and the stabilizer is preferably in the range of 0.5 to 100, more preferably in the range of 1 to 50, and still more preferably in the range of 2 to 25.
- the SZO external preparation of the present invention includes a solution or suspension in which the drug-containing complex is dissolved or dispersed in an oil phase. Whether it is a solution or a suspension depends on the type and amount of the surfactant and oil phase, and the presence or absence of ultrasonic treatment.
- the oil phase used in the present invention is not particularly limited as long as it is acceptable in pharmaceutical preparations.
- vegetable oils, animal oils, neutral lipids (mono-substituted, di-substituted or tri-substituted glycerides), synthetic fats and oils, sterols Derivatives can be mentioned.
- One of these may be selected and used, or two or more may be selected and mixed for use.
- one or more selected from the group consisting of soybean oil, sesame oil, olive oil, safflower oil, sunflower oil, rapeseed oil and perilla oil are used.
- triglyceride or a dietary oil containing this as a main component is used, and practically, soybean oil is preferable, and soybean oil purified to a high purity is particularly preferable.
- neutral lipids or long-chain fatty acid esters can also be suitably used, more preferably long-chain fatty acid esters, and still more preferably isopropyl myristate.
- the proportion of the oil phase in the solution or suspension contained in the szo-type external preparation of the present invention varies depending on the type of oil component and other components, but is within the range of 50 to 99.5 w / v%. A range ⁇ of 60 to 90 wZ v% is more preferable.
- an aqueous solution of a hydrophilic drug is prepared. Add stabilizers as needed.
- the water used here include pure water, purified water, distilled water, physiological saline, and buffer solution. If necessary, a small amount of a water-miscible organic solvent such as ethanol may be added. However, it should be noted that adding too much alcohol may make it difficult to form emulsions.
- the concentration of the hydrophilic drug and the stabilizer in the aqueous solution is not particularly limited as long as they can be dissolved substantially completely, but can be, for example, about 5 to 3 O mg Zml.
- an organic solvent solution of the surfactant is not particularly limited as long as it can dissolve the surfactant and can be diffused and removed in the next step.
- aliphatic hydrocarbons such as hexane
- aromatics such as toluene Carbonization.
- hydrogen examples include hydrogen.
- the concentration is not particularly limited, but for example:! ⁇ 10 mass. / Can be about 0 .
- an aqueous solution of a hydrophilic drug and a stabilizer and an organic solvent solution of a surfactant are mixed to prepare a WZO emulsion according to a conventional method.
- a stirrer such as a propeller mixer or disperser
- irradiate with ultrasonic waves for example, use high-speed stirring with a homogenizer, stir with a stirrer such as a propeller mixer or disperser, or irradiate with ultrasonic waves.
- the WZO type emulsion obtained in the above step (1) is dried to obtain a drug-containing complex.
- the drying method is not particularly limited and may be freeze-dried or dried under reduced pressure. However, lyophilization is preferred. Specific conditions may be in accordance with ordinary methods.
- it is preferable to remove moisture and organic solvent substantially completely. Moisture can cause chemical leakage within the product, and organic solvents can adversely affect the body. Specifically, for example, the water content may be reduced to 1% or less as measured by the Karl Fischer method.
- the SZO type solution or suspension is produced by dissolving or dispersing the drug-containing complex obtained in the above step (2) in the oil phase.
- step (1) high-speed stirring with a homogenizer, stirring with a stirrer such as a propeller mixer or disperser, or irradiation with ultrasonic waves in addition to these may be used. ,.
- the amount of the oil phase used in the process may be, for example, about 1 to 1 O mL per 1 g of the drug-containing complex, although it depends on the compatibility between the surfactant and the type of the oil phase.
- the obtained S / O type preparation may be further made into an S ZO / W type preparation by dispersing in an aqueous phase according to a conventional method.
- the solution or suspension may be applied to the affected area as it is, but is preferably formulated by adding other additive components.
- additives include, for example, excipients (for example, sugars such as sucrose; starch derivatives such as dextrin; cellulose derivatives such as carmello sanatrium; water-soluble polymers such as xanthan gum), colorants, lubricants ( For example, stearic acid metal salts such as calcium stearate and magnesium stearate; lauryl sulfate such as sodium lauryl sulfate and magnesium lauryl sulfate; starch derivatives in the above-mentioned excipients, etc., binders (for example, Excipients, macrogol, etc.), emulsifiers, thickeners, wetting agents (eg, devicesserin, etc.), stabilizers (eg, parahydroxybenzoates such as methylparaben, propylparaben; chlorobutanol, benzyl
- the above solution or suspension and other additive components can be mixed by conventional methods according to each dosage form to obtain ointments, lotions, aerosols, plasters, aqueous cataplasms, etc. Not.
- the dosage of the external preparation of the present invention may be adjusted according to the kind and amount of the drug to be added, the age and symptoms of the patient, and the like.
- the method for improving the transdermal absorbability of the hydrophilic drug according to the present invention is as follows.
- the percutaneous absorbability of a drug that has been difficult to use as an external preparation because of its low percutaneous absorbability, or that has not been sufficiently effective as an external preparation can be improved.
- the present invention will be described in more detail with reference to Examples and Test Examples, but the scope of the present invention is not limited to these.
- Diclofenac sodium (hereinafter referred to as “DFNa”) at a concentration of 15 mg / mL and bovine serum albumin (BSA, molecular weight: 69) at a concentration of 15 mg / mL into 1 OmL of 1 OmM phosphate buffer (pH 8.0) , 000).
- BSA bovine serum albumin
- DFNa- respect SZO type suspension 20 mass 0/0 A DFN a- S / O type ointment formulation was prepared with 10% by mass of macrogol, 5% by mass of decyl sebacate, and an appropriate amount of preservatives, and ⁇ serine as the remaining amount.
- Production Example 3 Production of D FN a—S / O lotion
- an aqueous cataplasm containing DFNa—SZO type was prepared. Ie made The DFNa—S / O type suspension manufactured in Preparation Example 1 was dissolved in polyethylene darcol, kneaded with other raw materials until uniform, spread directly on a polyester cloth, and cut into a desired size. Production Example 5 DFNa—SZO tape
- a DFNa—S / O type-containing aqueous tape preparation was prepared according to a conventional method.
- Diclofenac sodium (hereinafter referred to as “DFNa”) was dissolved in 1 OmL of 1 OmM phosphate buffer (pH 8.0) at a concentration of 15 mg / mL.
- DFNa Diclofenac sodium
- a percutaneous absorption test was carried out using the ears of a male New Zealand White rabbit weighing approximately 6. g. Immerse a brush with a width of about 1 Omm into the DFN a- S / O suspension (15 mg / mL) prepared in Formulation Example 1 and place it inside the left ear so that the DF Na 5 mg / kg per usa It was applied to an area of approximately 5 OmmX 5 Omm. After application, about 2 mL of blood was collected from the opposite ear, that is, the ear vein outside the right ear at 1, 2, 4, 6, 8, and 24 hours, and centrifuged to obtain plasma.
- Phosphoric acid and purified water were added to the plasma and charged into an extraction column (OAS IS MAX extraction cartridge, manufactured by Nihon Waters Co., Ltd.) previously activated with methanol and water.
- OAS IS MAX extraction cartridge manufactured by Nihon Waters Co., Ltd.
- methanol was eluted and washed, and then 5% methanol of formic acid was extracted as an eluent.
- DFNa soy oil suspension (l SmgZmL) produced in Comparative Production Example 1 was orally administered by means of a sonde at half the above dose (DFN a 2.5 mg / kg per rabbit weight). did. As described above, the blood concentration of DFNa was quantified.
- FIG. 1 shows that the DFN a- S / O suspension of Production Example 1 was applied as a transdermal absorbent to the inside of the left ear of the heel with 5 mg per kg of body weight, and the same heel was used to sandwich the drug holiday
- FIG. 5 shows changes in the blood concentration of DFNa when 2.5 mg / kg body weight of DFNa soybean oil suspension of Comparative Production Example 1 is orally administered for comparison.
- the Tmax of the percutaneous absorption preparation was almost the same as the oral preparation, equivalent to 2 hours, and showed an unprecedented speed of absorption.
- Cmax at that time is about 2.5 ⁇ gZmL, which is about half that of the oral preparation, and the blood concentration of DFNa is 1 at 24 hours.
- Test example 2 showing high sustainability as high as 98 ng / mL 2 Transdermal absorbability test
- a fixed amount of DFN a-SZO suspension of Formulation Example 1 was taken into a syringe and applied once to the application site at a dose of 5 mg / kg.
- Blood samples were collected using heparin-containing blood collection tubes at 7 time points after administration and 4, 8, 12, 24, 36, and 48 hours later, and the obtained blood was centrifuged to obtain plasma.
- the plasma concentration of DFNa was quantified in the same manner as in Test Example 1.
- a commercially available DFNa gel preparation manufactured by Novartis Pharma, Voltaren Gel
- the DFN a-SZO suspension (15 mg / mL) prepared in Formulation Example 1 is approximately 50 mm inside the left ear of a New Zealand White male rabbit with a weight of approximately 6.g. X was applied to an area of 50 mm.
- a commercially available DFNa gel preparation manufactured by Novartis Pharma Co., Voltaren Gel was applied to almost the same area.
- Figure 3 shows a photograph 24 hours after application.
- the transdermal absorbability of the hydrophilic drug is remarkably improved. Therefore, it is possible to use, as an external preparation, a drug that has been low in percutaneous absorption and has not been sufficiently effective as an external preparation. As a result, the drug can act directly on the affected area, and the risk of side effects can be reduced. Therefore, the method for improving the transdermal absorbability of the S / O type external preparation and the hydrophilic drug according to the present invention can expand the field of use of the hydrophilic drug that has a problem in the transdermal absorbability. It is extremely useful.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006532021A JP4843494B2 (ja) | 2004-08-31 | 2005-08-31 | S/o型外用剤 |
US11/661,292 US20090238846A1 (en) | 2004-08-31 | 2005-08-31 | S/O type external preparation |
EP05781929A EP1785131A4 (en) | 2004-08-31 | 2005-08-31 | EXTERNAL PREPARATION OF TYPE S / O |
IL181618A IL181618A0 (en) | 2004-08-31 | 2007-02-28 | Pharmaceutical solid-in-oil compositions for external administraton, methods for preparation and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004252829 | 2004-08-31 | ||
JP2004-252829 | 2004-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006025583A1 true WO2006025583A1 (ja) | 2006-03-09 |
Family
ID=36000217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/016355 WO2006025583A1 (ja) | 2004-08-31 | 2005-08-31 | S/o型外用剤 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20090238846A1 (ja) |
EP (1) | EP1785131A4 (ja) |
JP (1) | JP4843494B2 (ja) |
CN (1) | CN101022785A (ja) |
IL (1) | IL181618A0 (ja) |
TW (1) | TW200613004A (ja) |
WO (1) | WO2006025583A1 (ja) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008179561A (ja) * | 2007-01-24 | 2008-08-07 | Aspion Kk | S/o型経皮免疫剤 |
WO2009057808A1 (ja) | 2007-11-02 | 2009-05-07 | Aspion Co., Ltd. | 難溶性薬物-界面活性剤複合体製品とその製造法 |
WO2009139506A1 (ja) | 2008-05-15 | 2009-11-19 | Aspion株式会社 | 異なる物性の薬物の一剤形化 |
WO2010013350A1 (ja) | 2008-08-01 | 2010-02-04 | Aspion株式会社 | S/o型経皮免疫剤 |
JP2014172840A (ja) * | 2013-03-07 | 2014-09-22 | Lintec Corp | 貼付剤 |
WO2016006630A1 (ja) * | 2014-07-10 | 2016-01-14 | 積水化学工業株式会社 | 持続性全身作用型外用剤 |
WO2016043323A1 (ja) * | 2014-09-19 | 2016-03-24 | 積水化学工業株式会社 | 製剤及びその製造方法 |
JP2016060725A (ja) * | 2014-09-19 | 2016-04-25 | 積水化学工業株式会社 | コアシェル構造体及びそれを含有するs/o型サスペンション |
JP2016117681A (ja) * | 2014-12-19 | 2016-06-30 | 積水化学工業株式会社 | コアシェル構造体を含有する製剤 |
WO2017002865A1 (ja) * | 2015-06-29 | 2017-01-05 | 積水化学工業株式会社 | コアシェル構造体及び外用剤 |
JP2017014130A (ja) * | 2015-06-29 | 2017-01-19 | 積水化学工業株式会社 | 製剤 |
WO2017014306A1 (ja) * | 2015-07-22 | 2017-01-26 | 積水化学工業株式会社 | 製剤 |
WO2017111059A1 (ja) * | 2015-12-25 | 2017-06-29 | 積水化学工業株式会社 | 粒子、製剤、外用薬及び化粧品 |
JP2017114778A (ja) * | 2015-12-21 | 2017-06-29 | 積水化学工業株式会社 | 製剤 |
WO2017115838A1 (ja) * | 2015-12-28 | 2017-07-06 | 積水化学工業株式会社 | 外用剤及びその製造方法 |
JPWO2016167327A1 (ja) * | 2015-04-14 | 2018-02-08 | 日産化学工業株式会社 | ナノ機能性粒子 |
JP2018070535A (ja) * | 2016-11-01 | 2018-05-10 | 積水化学工業株式会社 | 有効成分含有粒子、製剤、外用薬、化粧品及び注射剤 |
JP6370520B1 (ja) * | 2017-02-09 | 2018-08-08 | 積水化学工業株式会社 | コアシェル構造体、製剤、外用薬、テープ剤及び化粧品 |
JP2018127453A (ja) * | 2017-02-10 | 2018-08-16 | 株式会社ツツミプランニング | 水溶性分子複合体、水溶性分子複合体含有油剤、及び分散液 |
JP2019011290A (ja) * | 2017-06-30 | 2019-01-24 | 小林製薬株式会社 | S/o型サスペンション及びその製造方法 |
JPWO2018124043A1 (ja) * | 2016-12-28 | 2019-10-31 | 小林製薬株式会社 | 外用組成物 |
WO2019230939A1 (ja) | 2018-05-31 | 2019-12-05 | 国立大学法人九州大学 | 経皮吸収性製剤 |
JP2020033293A (ja) * | 2018-08-29 | 2020-03-05 | 東洋インキScホールディングス株式会社 | 皮膚貼付用粘着剤、該粘着剤を用いた皮膚貼付剤及び剥離用シート状部材付き皮膚用貼付剤の製造方法 |
US10729661B2 (en) | 2014-12-19 | 2020-08-04 | Sekisui Chemical Co., Ltd. | Preparation |
WO2020203809A1 (ja) * | 2019-03-29 | 2020-10-08 | 日産化学株式会社 | レシチンs/o製剤の新規製造方法及びその製剤 |
JPWO2021049529A1 (ja) * | 2019-09-13 | 2021-03-18 | ||
JP2021059521A (ja) * | 2019-10-09 | 2021-04-15 | 積水化学工業株式会社 | 製剤 |
WO2021075491A1 (ja) | 2019-10-16 | 2021-04-22 | 国立大学法人九州大学 | 経皮吸収型貼付剤 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012152655A (ja) * | 2011-01-21 | 2012-08-16 | Biomedix:Kk | S/o型サスペンションの製造方法 |
JP2019069913A (ja) * | 2017-10-06 | 2019-05-09 | 株式会社シャネル化粧品技術開発研究所 | 非水系皮膚外用組成物の製造方法 |
JP2019069912A (ja) * | 2017-10-06 | 2019-05-09 | 株式会社シャネル化粧品技術開発研究所 | 非水系皮膚外用組成物およびその製造方法 |
WO2019102992A1 (ja) | 2017-11-21 | 2019-05-31 | 積水化学工業株式会社 | 皮膚外用剤 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58150508A (ja) * | 1982-03-02 | 1983-09-07 | Mitsubishi Chem Ind Ltd | 皮膚用製剤 |
JPH0558884A (ja) * | 1991-02-11 | 1993-03-09 | American Home Prod Corp | 鎮痛薬組成物 |
JPH0912452A (ja) * | 1995-06-27 | 1997-01-14 | Ss Pharmaceut Co Ltd | ジクロフェナクナトリウム含有乳化外用剤 |
JP2004043355A (ja) * | 2002-07-11 | 2004-02-12 | Mitsubishi-Kagaku Foods Corp | O/w型エマルション製剤 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1417003A (en) * | 1972-06-22 | 1975-12-10 | Radiochemical Centre Ltd | Stabilisation of fibrinogen |
JPS60100516A (ja) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
IT1229489B (it) * | 1988-12-09 | 1991-09-03 | Altergon Sa | Composizioni farmaceutiche lipidiche per uso topico atte a veicolare un principio attivo antiinfiammatorio idrosolubile |
JP3526887B2 (ja) * | 1993-04-23 | 2004-05-17 | 帝國製薬株式会社 | 消炎鎮痛外用貼付剤 |
GB9424902D0 (en) * | 1994-12-09 | 1995-02-08 | Cortecs Ltd | Solubilisation Aids |
IT1295369B1 (it) * | 1997-10-21 | 1999-05-12 | Fatro Spa | Composizione a base di tiamfenicolo e diclofenac |
WO2000047203A1 (en) * | 1999-02-12 | 2000-08-17 | Mqs, Inc. | Formulation and system for intra-oral delivery of pharmaceutical agents |
IT1312088B1 (it) * | 1999-04-21 | 2002-04-04 | Altergon Sa | Cerotto per uso topico contenente eparina e diclofenac. |
AU5936400A (en) * | 1999-06-04 | 2000-12-28 | Delrx Pharmaceutical Corporation | Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
DK1277466T3 (da) * | 2000-04-18 | 2011-10-17 | Hisamitsu Pharmaceutical Co | Plaster indeholdende et antiinflammatorisk middel |
KR100463167B1 (ko) * | 2001-04-13 | 2004-12-23 | 주식회사 태평양 | 고분자 나노입자를 이용한 경피흡수제 및 이를 함유한외용제 조성물 |
JP4269078B2 (ja) * | 2002-06-03 | 2009-05-27 | 宮崎県 | S/o/wエマルション及びその製造方法 |
US6936273B2 (en) * | 2002-12-20 | 2005-08-30 | Idexx Laboratories, Inc. | Liposomal analgesic formulation and use |
-
2005
- 2005-08-31 CN CNA2005800275041A patent/CN101022785A/zh active Pending
- 2005-08-31 US US11/661,292 patent/US20090238846A1/en not_active Abandoned
- 2005-08-31 EP EP05781929A patent/EP1785131A4/en not_active Withdrawn
- 2005-08-31 JP JP2006532021A patent/JP4843494B2/ja active Active
- 2005-08-31 WO PCT/JP2005/016355 patent/WO2006025583A1/ja active Application Filing
- 2005-08-31 TW TW094129900A patent/TW200613004A/zh unknown
-
2007
- 2007-02-28 IL IL181618A patent/IL181618A0/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58150508A (ja) * | 1982-03-02 | 1983-09-07 | Mitsubishi Chem Ind Ltd | 皮膚用製剤 |
JPH0558884A (ja) * | 1991-02-11 | 1993-03-09 | American Home Prod Corp | 鎮痛薬組成物 |
JPH0912452A (ja) * | 1995-06-27 | 1997-01-14 | Ss Pharmaceut Co Ltd | ジクロフェナクナトリウム含有乳化外用剤 |
JP2004043355A (ja) * | 2002-07-11 | 2004-02-12 | Mitsubishi-Kagaku Foods Corp | O/w型エマルション製剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1785131A4 * |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008179561A (ja) * | 2007-01-24 | 2008-08-07 | Aspion Kk | S/o型経皮免疫剤 |
JPWO2009057808A1 (ja) * | 2007-11-02 | 2011-03-17 | Aspion株式会社 | 難溶性薬物−界面活性剤複合体製品とその製造法 |
WO2009057808A1 (ja) | 2007-11-02 | 2009-05-07 | Aspion Co., Ltd. | 難溶性薬物-界面活性剤複合体製品とその製造法 |
JP2014088453A (ja) * | 2008-05-15 | 2014-05-15 | Cocokara Fine Next Co Ltd | 異なる物性の薬物の一剤形化 |
JPWO2009139506A1 (ja) * | 2008-05-15 | 2011-09-22 | Soファーマ株式会社 | 異なる物性の薬物の一剤形化 |
JP5485879B2 (ja) * | 2008-05-15 | 2014-05-07 | 株式会社ココカラファインネクスト | 異なる物性の薬物の一剤形化 |
WO2009139506A1 (ja) | 2008-05-15 | 2009-11-19 | Aspion株式会社 | 異なる物性の薬物の一剤形化 |
WO2010013350A1 (ja) | 2008-08-01 | 2010-02-04 | Aspion株式会社 | S/o型経皮免疫剤 |
US20110159035A1 (en) * | 2008-08-01 | 2011-06-30 | Masahiro Goto | S/o type transdermal immunizing agent |
JP2014172840A (ja) * | 2013-03-07 | 2014-09-22 | Lintec Corp | 貼付剤 |
WO2016006630A1 (ja) * | 2014-07-10 | 2016-01-14 | 積水化学工業株式会社 | 持続性全身作用型外用剤 |
WO2016043323A1 (ja) * | 2014-09-19 | 2016-03-24 | 積水化学工業株式会社 | 製剤及びその製造方法 |
JP2016060725A (ja) * | 2014-09-19 | 2016-04-25 | 積水化学工業株式会社 | コアシェル構造体及びそれを含有するs/o型サスペンション |
US10130710B2 (en) | 2014-09-19 | 2018-11-20 | Sekisui Chemical Co., Ltd. | Formulation and method for producing same |
CN108078921A (zh) * | 2014-09-19 | 2018-05-29 | 积水化学工业株式会社 | 制剂及其制造方法 |
EP3287125A1 (en) | 2014-09-19 | 2018-02-28 | Sekisui Chemical Co., Ltd. | Formulation and method for producing same |
JP2016117681A (ja) * | 2014-12-19 | 2016-06-30 | 積水化学工業株式会社 | コアシェル構造体を含有する製剤 |
US10729661B2 (en) | 2014-12-19 | 2020-08-04 | Sekisui Chemical Co., Ltd. | Preparation |
JPWO2016167327A1 (ja) * | 2015-04-14 | 2018-02-08 | 日産化学工業株式会社 | ナノ機能性粒子 |
WO2017002865A1 (ja) * | 2015-06-29 | 2017-01-05 | 積水化学工業株式会社 | コアシェル構造体及び外用剤 |
JPWO2017002865A1 (ja) * | 2015-06-29 | 2017-06-29 | 積水化学工業株式会社 | コアシェル構造体及び外用剤 |
JP2017014130A (ja) * | 2015-06-29 | 2017-01-19 | 積水化学工業株式会社 | 製剤 |
US10561603B2 (en) | 2015-06-29 | 2020-02-18 | Sekisui Chemical Co., Ltd. | Core-shell structure and topical agent |
WO2017014306A1 (ja) * | 2015-07-22 | 2017-01-26 | 積水化学工業株式会社 | 製剤 |
JP2017114778A (ja) * | 2015-12-21 | 2017-06-29 | 積水化学工業株式会社 | 製剤 |
JPWO2017111059A1 (ja) * | 2015-12-25 | 2017-12-21 | 積水化学工業株式会社 | 粒子、製剤、外用薬及び化粧品 |
WO2017111059A1 (ja) * | 2015-12-25 | 2017-06-29 | 積水化学工業株式会社 | 粒子、製剤、外用薬及び化粧品 |
WO2017115838A1 (ja) * | 2015-12-28 | 2017-07-06 | 積水化学工業株式会社 | 外用剤及びその製造方法 |
JP6212674B1 (ja) * | 2015-12-28 | 2017-10-11 | 積水化学工業株式会社 | 外用剤及びその製造方法 |
JP2018070535A (ja) * | 2016-11-01 | 2018-05-10 | 積水化学工業株式会社 | 有効成分含有粒子、製剤、外用薬、化粧品及び注射剤 |
JPWO2018124043A1 (ja) * | 2016-12-28 | 2019-10-31 | 小林製薬株式会社 | 外用組成物 |
US11253470B2 (en) | 2016-12-28 | 2022-02-22 | Kobayashi Pharmaceutical Co., Ltd. | Composition for external application |
AU2018218868B2 (en) * | 2017-02-09 | 2023-06-29 | Sekisui Chemical Co., Ltd. | Core-shell structure, preparation, medicine for external application, tape agent and cosmetic product |
RU2754031C2 (ru) * | 2017-02-09 | 2021-08-25 | Секисуй Кемикал Ко., Лтд. | Структура ядро-оболочка, получение, лекарственное средство для наружного применения, средство в виде ленты и косметический продукт |
JP2019052135A (ja) * | 2017-02-09 | 2019-04-04 | 積水化学工業株式会社 | コアシェル構造体、製剤、外用薬、テープ剤及び化粧品 |
WO2018147333A1 (ja) * | 2017-02-09 | 2018-08-16 | 積水化学工業株式会社 | コアシェル構造体、製剤、外用薬、テープ剤及び化粧品 |
JP2019052138A (ja) * | 2017-02-09 | 2019-04-04 | 積水化学工業株式会社 | コアシェル構造体、製剤、外用薬、テープ剤及び化粧品 |
JP6386691B1 (ja) * | 2017-02-09 | 2018-09-05 | 積水化学工業株式会社 | コアシェル構造体、製剤、外用薬、テープ剤及び化粧品 |
JP6370520B1 (ja) * | 2017-02-09 | 2018-08-08 | 積水化学工業株式会社 | コアシェル構造体、製剤、外用薬、テープ剤及び化粧品 |
JP2018127453A (ja) * | 2017-02-10 | 2018-08-16 | 株式会社ツツミプランニング | 水溶性分子複合体、水溶性分子複合体含有油剤、及び分散液 |
JP7039197B2 (ja) | 2017-06-30 | 2022-03-22 | 小林製薬株式会社 | S/o型サスペンション及びその製造方法 |
JP2019011290A (ja) * | 2017-06-30 | 2019-01-24 | 小林製薬株式会社 | S/o型サスペンション及びその製造方法 |
KR20210028609A (ko) | 2018-05-31 | 2021-03-12 | 고쿠리쓰다이가쿠호진 규슈다이가쿠 | 경피 흡수성 제제 |
WO2019230939A1 (ja) | 2018-05-31 | 2019-12-05 | 国立大学法人九州大学 | 経皮吸収性製剤 |
JP2020033293A (ja) * | 2018-08-29 | 2020-03-05 | 東洋インキScホールディングス株式会社 | 皮膚貼付用粘着剤、該粘着剤を用いた皮膚貼付剤及び剥離用シート状部材付き皮膚用貼付剤の製造方法 |
JP7047672B2 (ja) | 2018-08-29 | 2022-04-05 | 東洋インキScホールディングス株式会社 | 皮膚貼付用粘着剤、該粘着剤を用いた皮膚貼付剤及び剥離用シート状部材付き皮膚用貼付剤の製造方法 |
WO2020203809A1 (ja) * | 2019-03-29 | 2020-10-08 | 日産化学株式会社 | レシチンs/o製剤の新規製造方法及びその製剤 |
WO2021049529A1 (ja) * | 2019-09-13 | 2021-03-18 | 積水化学工業株式会社 | 製剤 |
JP7227271B2 (ja) | 2019-09-13 | 2023-02-21 | 積水化学工業株式会社 | 製剤 |
JPWO2021049529A1 (ja) * | 2019-09-13 | 2021-03-18 | ||
JP2021059521A (ja) * | 2019-10-09 | 2021-04-15 | 積水化学工業株式会社 | 製剤 |
WO2021075491A1 (ja) | 2019-10-16 | 2021-04-22 | 国立大学法人九州大学 | 経皮吸収型貼付剤 |
KR20220083738A (ko) | 2019-10-16 | 2022-06-20 | 고쿠리쓰다이가쿠호진 규슈다이가쿠 | 경피 흡수형 첩부제 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2006025583A1 (ja) | 2008-05-08 |
EP1785131A4 (en) | 2009-03-11 |
US20090238846A1 (en) | 2009-09-24 |
IL181618A0 (en) | 2007-07-04 |
CN101022785A (zh) | 2007-08-22 |
TW200613004A (en) | 2006-05-01 |
EP1785131A1 (en) | 2007-05-16 |
EP1785131A8 (en) | 2007-08-01 |
JP4843494B2 (ja) | 2011-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4843494B2 (ja) | S/o型外用剤 | |
JP3903061B2 (ja) | 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤 | |
EP0974350B1 (en) | External preparation containing tranilast and process for producing the same | |
KR20230110821A (ko) | 염증성 피부 질환을 치료하기 위한 국소 조성물 및방법 | |
CA2749941C (en) | Ibuprofen for topical administration | |
CN103565743B (zh) | 氨甲环酸皮肤外用纳米制剂及其制备方法和用途 | |
WO2005094789A1 (ja) | S/o型製剤およびその製造方法 | |
EP3853204A1 (en) | Improved and stable apremilast pharmaceutical compositions | |
Yukselen et al. | Ketotifen ameliorates development of fibrosis in alkali burns of the esophagus | |
US10792293B2 (en) | Topical nanodrug formulation | |
JP5752343B2 (ja) | S/o型経皮免疫剤 | |
JPH10139661A (ja) | 新規な治療用抗炎症鎮痛医薬組成物およびその製造法 | |
WO2010013350A1 (ja) | S/o型経皮免疫剤 | |
JP4813725B2 (ja) | 鎮痒用外用剤 | |
JP4791682B2 (ja) | 痔疾患用治療剤 | |
US11376213B2 (en) | Topical pharmaceutical formulation | |
JPH06321771A (ja) | 経皮投与用基剤 | |
JP4313003B2 (ja) | 血液透析による皮膚疾患及び痒みの治療用外用剤 | |
CA2244679C (en) | Tranilast-containing preparation for external application and method of producing the same | |
KR20230097862A (ko) | 리도카인 또는 이의 약학적으로 허용가능한 염 및 글리세린모노스테아레이트를 포함하는 치질치료용 약학적 조성물 | |
BR112021008677A2 (pt) | composições farmacêuticas tópicas de teriflunomida, processo de preparação e uso | |
JP2004137215A (ja) | 有痛性皮膚創傷の治療用外用剤 | |
JP2004292341A (ja) | ケロイド等の形成抑制外用剤 | |
JPS61186311A (ja) | 軟膏基剤 | |
JP2005213192A (ja) | 消炎鎮痛外用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006532021 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580027504.1 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005781929 Country of ref document: EP Ref document number: 11661292 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 181618 Country of ref document: IL Ref document number: 747/KOLNP/2007 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005781929 Country of ref document: EP |